|Bid||0.260 x 0|
|Ask||0.280 x 0|
|Day's Range||0.240 - 0.250|
|52 Week Range||0.220 - 0.450|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.65|
HOUSTON and VANCOUVER , Feb. 13, 2018 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies ...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2017
NEW YORK, NY / ACCESSWIRE / February 6, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
Nasdaq: EPIX) ("ESSA" or the "Company") today announced that David R. Parkinson, President and Chief Executive Officer, will present at NobleCon14 - Noble Capital Markets' Fourteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida - on Monday January 29th at 1:30pm Eastern Standard Time.
Nasdaq: EPIX) ("ESSA" or the "Company") announced today that Frank Perabo, M.D., Ph.D., will depart ESSA as the Company's Chief Medical Officer to pursue other opportunities, effective January 31, 2018. Dr. Perabo will continue to serve the Company in an advisory capacity, and as a member of ESSA's medical advisory committee. ESSA announced in September 2017, its intention to cease clinical development of EPI-506 and utilize the results from the successfully completed Phase 1 proof of concept trial to expand the preclinical development program around more potent next-generation aniten molecules. Within the next-generation program, the Company expects to file an Investigational New Drug filing and initiate a Phase 1 clinical trial of the selected next-generation molecule in the first quarter of 2019. ESSA recently announced the completion of an approximately US$26 million financing to fund preclinical and clinical development within its next-generation Aniten program.
NASDAQ: EPIX) ("ESSA" or the "Company") announces a further update to its previously announced equity offering. As previously announced, the Company intends to issue up to 125,000,000 common shares of the Company ("Common Shares") at a price of US$0.20 per Common Share (the "Offering Price") for aggregate gross proceeds of up to US$25 million (the "Offering").
VANCOUVER , Dec. 13, 2017 /CNW/ - Trading resumes in: Company: ESSA PHARMA INC TSX-Venture Symbol: EPI Resumption (ET): 9:50 AM IIROC can make a decision to impose a temporary suspension (halt) of trading ...
VANCOUVER , Dec. 13, 2017 /CNW/ - The following issues have been halted by IIROC: Company: ESSA PHARMA INC TSX-Venture Symbol: EPI Reason: At the Request of the Company Pending News Halt Time (ET): 8:45 ...